Literature DB >> 33437209

P-cresol and Indoxyl Sulfate Impair Osteogenic Differentiation by Triggering Mesenchymal Stem Cell Senescence.

Witchayapon Kamprom1, Tulyapruek Tawonsawatruk2, Sumana Mas-Oodi3, Korrarit Anansilp3, Manoch Rattanasompattikul4, Aungkura Supokawej5.   

Abstract

Chronic kidney disease (CKD) patients obtained high levels of uremic toxins progressively develop several complications including bone fractures. Protein-bound uremic toxins especially p-cresol and indoxyl sulfate are hardly eliminated due to their high molecular weight. Thus, the abnormality of bone in CKD patient could be potentially resulted from the accumulation of uremic toxins. To determine whether protein-bound uremic toxins have an impact on osteogenesis, mesenchymal stem cells were treated with either p-cresol or indoxyl sulfate under in vitro osteogenic differentiation. The effects of uremic toxins on MSC-osteoblastic differentiation were investigated by evaluation of bone phenotype. The results demonstrated that p-cresol and indoxyl sulfate down-regulated the transcriptional level of collagen type I, deceased alkaline phosphatase activity, and impaired mineralization of MSC-osteoblastic cells. Furthermore, p-cresol and indoxyl sulfate gradually increased senescence-associated beta-galactosidase positive cells while upregulated the expression of p21 which participate in senescent process. Our findings clearly revealed that the presence of uremic toxins dose-dependently influenced a gradual deterioration of osteogenesis. The effects partially mediate through the activation of senescence-associated gene lead to the impairment of osteogenesis. Therefore, the management of cellular senescence triggered by uremic toxins could be considered as an alternative therapeutic approach to prevent bone abnormality in CKD patients. © The author(s).

Entities:  

Keywords:  cellular senescence; chronic kidney disease; indoxyl sulfate; mesenchymal stem cells; osteogenesis; p-cresol

Year:  2021        PMID: 33437209      PMCID: PMC7797544          DOI: 10.7150/ijms.48492

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


  45 in total

Review 1.  Chronic Kidney Disease.

Authors:  Angela C Webster; Evi V Nagler; Rachael L Morton; Philip Masson
Journal:  Lancet       Date:  2016-11-23       Impact factor: 79.321

2.  Improved dialytic removal of protein-bound uremic toxins by intravenous lipid emulsion in chronic kidney disease rats.

Authors:  Yuanyuan Shi; Yumei Zhang; Huajun Tian; Yifeng Wang; Yue Shen; Qiuyu Zhu; Feng Ding
Journal:  Nephrol Dial Transplant       Date:  2019-11-01       Impact factor: 5.992

Review 3.  Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients.

Authors:  Masaomi Nangaku; Imari Mimura; Junna Yamaguchi; Yoshiki Higashijima; Takehiko Wada; Tetsuhiro Tanaka
Journal:  J Ren Nutr       Date:  2014-12-30       Impact factor: 3.655

Review 4.  The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.

Authors:  Katherine Wesseling-Perry; Harald Jüppner
Journal:  Bone       Date:  2012-10-16       Impact factor: 4.398

5.  Identification of Senescent Cells in the Bone Microenvironment.

Authors:  Joshua N Farr; Daniel G Fraser; Haitao Wang; Katharina Jaehn; Mikolaj B Ogrodnik; Megan M Weivoda; Matthew T Drake; Tamara Tchkonia; Nathan K LeBrasseur; James L Kirkland; Lynda F Bonewald; Robert J Pignolo; David G Monroe; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2016-10-24       Impact factor: 6.741

Review 6.  Examination of the expanding pathways for the regulation of p21 expression and activity.

Authors:  Yong-Sam Jung; Yingjuan Qian; Xinbin Chen
Journal:  Cell Signal       Date:  2010-01-25       Impact factor: 4.315

7.  Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption.

Authors:  Kenta Watanabe; Tsukasa Tominari; Michiko Hirata; Chiho Matsumoto; Junya Hirata; Gillian Murphy; Hideaki Nagase; Chisato Miyaura; Masaki Inada
Journal:  FEBS Open Bio       Date:  2017-07-20       Impact factor: 2.693

8.  Indoxyl sulfate promotes apoptosis in cultured osteoblast cells.

Authors:  Young-Hee Kim; Kyung-Ah Kwak; Hyo-Wook Gil; Ho-Yeon Song; Sae-Yong Hong
Journal:  BMC Pharmacol Toxicol       Date:  2013-12-01       Impact factor: 2.483

Review 9.  Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction.

Authors:  Hideki Fujii; Shunsuke Goto; Masafumi Fukagawa
Journal:  Toxins (Basel)       Date:  2018-05-16       Impact factor: 4.546

10.  AST-120 Reduces Neuroinflammation Induced by Indoxyl Sulfate in Glial Cells.

Authors:  Simona Adesso; Irene Paterniti; Salvatore Cuzzocrea; Masaki Fujioka; Giuseppina Autore; Tim Magnus; Aldo Pinto; Stefania Marzocco
Journal:  J Clin Med       Date:  2018-10-17       Impact factor: 4.241

View more
  3 in total

1.  Indoxyl sulfate impairs in vitro erythropoiesis by triggering apoptosis and senescence.

Authors:  Thitinat Duangchan; Manoch Rattanasompattikul; Narong Chitchongyingcharoen; Sumana Mas-Oodi; Moltira Promkan; Nuttawut Rongkiettechakorn; Suksan Korpraphong; Aungkura Supokawej
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-25

Review 2.  Mechanisms during Osteogenic Differentiation in Human Dental Follicle Cells.

Authors:  Christian Morsczeck
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 3.  Interplay between gut microbiota, bone health and vascular calcification in chronic kidney disease.

Authors:  Fernanda G Rodrigues; Milene S Ormanji; Ita P Heilberg; Stephan J L Bakker; Martin H de Borst
Journal:  Eur J Clin Invest       Date:  2021-06-07       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.